Ratings by Piper Sandler (Matthew O'Brien)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
5/6/2026 Alphatec Holdings ATEC Maintain Overweight
(N/A)
 
 
  Details
10/31/2025 Alphatec Holdings ATEC Maintain
(N/A)
 
 
  Details
2/27/2025 Alphatec Holdings ATEC Maintain Overweight
(N/A)
 
 
  Details
7/1/2024 Zimmer Biomet ZBH Downgrade Neutral
(Overweight)
108.38
(100.91)
-6.89% Details
11/7/2023 Alphatec Holdings ATEC Maintain Overweight
(N/A)
 
 
  Details
3/10/2023 Zimmer Biomet ZBH Upgrade Overweight
(Neutral)
121.91
(100.91)
-17.23% Details
3/1/2023 Alphatec Holdings ATEC Maintain Overweight
(N/A)
 
 
  Details
2/23/2023 Integra LifeSciences IART Maintain Neutral
(N/A)
 
 
  Details
1/6/2023 Repro Med Systems KRMD Maintain Overweight
(N/A)
 
 
  Details
11/15/2022 Aziyo Biologics Inc. AZYO Maintain Overweight
(N/A)
 
 
  Details
11/10/2022 Repro Med Systems KRMD Upgrade Overweight
(Neutral)
2.31
(4.65)
101.3% Details
3/2/2022 Alphatec Holdings ATEC Maintain Overweight
(N/A)
 
 
  Details
2/23/2022 Integra LifeSciences IART Maintain Neutral
(N/A)
 
 
  Details
1/4/2022 Zimmer Biomet ZBH Downgrade Neutral
(Overweight)
127.04
(100.91)
-20.57% Details
11/10/2021 Aziyo Biologics Inc. AZYO Maintain Overweight
(N/A)
 
 
  Details
11/5/2021 Zimmer Biomet ZBH Maintain Overweight
(N/A)
 
 
  Details
3/24/2021 Repro Med Systems KRMD Maintain Neutral
(N/A)
 
 
  Details
1/26/2021 Repro Med Systems KRMD Downgrade Neutral
(Overweight)
5.18
(3.33)
-35.71% Details
11/6/2020 Alphatec Holdings ATEC Maintain Overweight
(N/A)
 
 
  Details
11/2/2020 Aziyo Biologics Inc. AZYO New Coverage Overweight
(N/A)
10.82
(1.49)
-86.23% Details
6/24/2020 Repro Med Systems KRMD New Coverage Overweight
(N/A)
9.50
(3.33)
-64.95% Details
1/7/2020 Zimmer Biomet ZBH Upgrade Overweight
(Neutral)
147.95
(100.91)
-31.79% Details
1/7/2020 Integra LifeSciences IART Downgrade Neutral
(Overweight)
57.37
(17.95)
-68.71% Details
10/31/2019 Alphatec Holdings ATEC Maintain Overweight
(N/A)
 
 
  Details